Medicaid Expansion Drove 21% Surge in Opioid Treatment Access, Oklahoma Study Shows

When Oklahoma voters approved Medicaid expansion in 2020, they were promised better healthcare access for working families. Six years later, the data reveals a dramatic secondary benefit: a 43% drop in drug overdose deaths, among the steepest declines in the nation. The mechanism behind this improvement isn't mysterious—it's medication.

A study published in February in JAMA Network Open traces how Medicaid expansion across eight states that adopted the policy after 2018 triggered a more than 21% increase in prescriptions for buprenorphine, the gold-standard medication for treating opioid use disorder. The research, led by Nicole Siegal at Indiana University and Stephen Crystal at Rutgers University, analyzed pharmacy claims data from over 4.5 million patients nationwide.

The findings arrive at a politically fraught moment. Congressional Republicans are pursuing deep Medicaid cuts that could strip coverage from millions of Americans. At least nine states have enacted "trigger laws" requiring them to roll back expansion if federal funding drops. Oklahoma lawmakers are currently considering two such measures, though both would require voter approval given that the state enshrined expansion in its constitution.

The Numbers Behind the Trend

Between 2019 and 2023, the eight most recent Medicaid expansion states—Idaho, Maine, Missouri, North Carolina, Oklahoma, South Dakota, Utah, and Virginia—saw buprenorphine prescriptions rise by 21.1% relative to non-expansion states. That translates to 28.67 additional prescriptions per 100,000 residents.

The effect wasn't limited to Medicaid recipients. Even patients with private insurance or no insurance saw increased access, suggesting that expanded coverage created systemic changes in how treatment was delivered. "It's not just a shift of patients going from one source to another," Siegal explained. "Expanded health care coverage allowed a larger number of people to get prescriptions."

Researchers estimate these additional prescriptions averted up to 140 overdose deaths annually across the expansion states. In Oklahoma specifically, the 43% reduction in overdose deaths during 2025 represents one of the most significant improvements in the country.

Why Earlier Studies Missed the Connection

Previous research on Medicaid expansion's impact on opioid treatment yielded mixed results. Some studies of the initial wave of expansion states—those that adopted the policy in 2014—found only modest improvements in treatment rates. Crystal believes the difference lies in timing.

"Earlier studies did not find major improvements in overall treatment rates, but this new analysis shows that in the current era of treatment policy, where many of the old barriers have been lifted, Medicaid expansion is not just helpful, but essential," he said.

The policy landscape shifted dramatically between 2014 and 2019. The X-waiver requirement that restricted which clinicians could prescribe buprenorphine was eliminated in 2023. Telehealth regulations loosened during the COVID-19 pandemic and largely remained relaxed. States increasingly authorized outpatient medication treatment rather than requiring intensive clinic-based programs. These changes created an environment where insurance coverage could translate directly into treatment access.

The Medicaid Factor

Medicaid has become the dominant payer for opioid use disorder treatment in the United States. According to KFF, the health policy research organization, Medicaid covered medication for nearly half of all non-elderly adults with opioid use disorder in 2023. In Oklahoma, expansion currently covers approximately 228,000 residents.

Crystal, who has published multiple studies on buprenorphine trends, calls Oklahoma a "success story" for how Medicaid expansion can drive public health improvements. But he warns that these gains are fragile.

"I don't know how you would maintain the current level of buprenorphine treatment if you eliminated Medicaid expansion because the expansion population is where you find a lot of the people with opioid use disorder," he said.

The mathematics are stark. Buprenorphine reduces overdose mortality by approximately 50% compared to no treatment. Each percentage point increase in treatment coverage translates to measurable lives saved. Conversely, each barrier to access—whether financial, regulatory, or geographic—carries a mortality cost.

The Political Crossroads

The JAMA study's publication coincides with intense debate over federal healthcare spending. The Trump administration's FY2027 budget proposal includes deep cuts to Medicaid and the consolidation of behavioral health grant programs. Congressional Republicans have indicated support for reducing federal Medicaid contributions, which would force states to either absorb costs or reduce eligibility.

Oklahoma's constitutional protection for Medicaid expansion makes it relatively resilient compared to states where legislatures can unwind coverage unilaterally. But even constitutional guarantees don't create money where none exists. If federal matching funds drop significantly, Oklahoma would face the same choices as other expansion states: raise revenue, cut other programs, or reduce healthcare access.

The research team plans to present their findings at the 2026 AcademyHealth Annual Research Meeting in Seattle this May. The timing places their data squarely in the middle of policy discussions that will shape addiction treatment access for years to come.

Beyond the Statistics

While the 21% increase in prescriptions and 43% reduction in overdose deaths make compelling headlines, the study's deeper significance lies in what it reveals about the relationship between healthcare financing and addiction outcomes. Opioid use disorder disproportionately affects low-income adults—the exact population Medicaid expansion targets. Without insurance, the monthly cost of buprenorphine treatment can exceed $500, placing it out of reach for many who need it most.

The research also underscores how policy changes interact. The elimination of the X-waiver, telehealth expansion, and Medicaid coverage created a synergistic effect where each reform amplified the others. Buprenorphine prescribing increased not just because more people had insurance, but because the system had become more flexible in how that insurance could be used.

Whether this flexibility survives the current political environment remains an open question. What the Oklahoma data makes clear is that the stakes extend far beyond budget spreadsheets. In the first three years after expansion, hundreds of Oklahomans received treatment who otherwise would have gone without. Some of them are alive today because of it.

---

The study, "Medicaid Expansion and Buprenorphine Dispensing in Early vs Recent Expansion States," was published in JAMA Network Open on February 28, 2026.